The EUnetHTA Rolling Collaborative Reviews (RCR) aim to provide decision-makers with a timely synthesis of available evidence on the comparative effectiveness of currently 15 therapeutic health technologies relevant to the management of the current covid-19 pandemic. The first round of these monthly updated reviews has been published. KCE is covering the generic drugs camostat and nafamostat.